Restless Legs Syndrome: Symptoms, Diagnosis, and Treatment

Restless legs syndrome (RLS) is a neurological sleep-related movement disorder that creates an urge to move the legs during rest. Movement brings at least temporary relief, and the pattern is usually strongest in the evening or at night. Uncomfortable sensations may accompany the urge, but pain, tingling, or twitching by themselves do not establish RLS ¹².

RLS is also called Willis-Ekbom disease. It can be occasional or persistent. When symptoms repeatedly delay sleep, interrupt quiet activities, or affect daytime function, a clinician can confirm whether the pattern meets the diagnostic criteria and look for factors that may be treatable.

The four core features of RLS

The International Restless Legs Syndrome Study Group defines four symptom features that must occur together ¹:

1. An urge to move the legs. Unpleasant sensations may be present, but the urge is the central feature. Some people describe pulling, crawling, buzzing, itching, aching, or an internal restlessness that is difficult to name.
2. The urge begins or becomes worse during rest. Sitting or lying still brings it on or makes it stronger.
3. Movement partially or completely relieves it. Walking, stretching, or moving the legs helps for at least as long as the movement continues.
4. It occurs mainly in the evening or at night. Symptoms at rest are worse later in the day than they are earlier, or occur only in the evening or at night.

A fifth diagnostic requirement is equally important: another medical or behavioral condition must not better explain the pattern. This exclusion criterion was added because cramps, neuropathy, medication-related restlessness, and ordinary positional discomfort can satisfy parts of the four-feature description ¹.

Severe or long-standing RLS can begin earlier in the day, and symptoms can sometimes involve the arms. That does not remove the need to establish the characteristic rest, movement, and time-of-day pattern. A clinician should also consider medication-related augmentation if treated symptoms have progressively shifted earlier or spread beyond their prior distribution ².

What RLS is often confused with

RLS is diagnosed from the whole pattern, not from a single word such as “tingling” or “restless.” These distinctions can help during a clinical history ³²:

Condition or finding	How it differs from a typical RLS pattern
Nocturnal leg cramp	A muscle suddenly tightens into a painful knot. The main problem is cramping rather than an urge to move, and stretching the affected muscle may end the episode.
Peripheral neuropathy or radiculopathy	Burning, numbness, altered sensation, or pain may continue during activity and may not follow a rest-related evening pattern. Weakness, reduced sensation, or reflex changes point away from uncomplicated RLS.
Akathisia	This is an inner restlessness, often involving much of the body and sometimes related to a medicine. It may lack the evening predominance and dependable relief with movement seen in RLS.
Positional discomfort	Pressure or discomfort occurs in a particular position and resolves after one adjustment. RLS usually returns when movement stops and rest continues.
Periodic limb movements during sleep	These are involuntary, repetitive movements recorded during sleep. They do not require a conscious urge and can occur with RLS, sleep apnea, narcolepsy, other conditions, or on their own.

Leg swelling, arthritis, venous disease, local injury, and habitual movements can also mimic parts of RLS. Some conditions can coexist with RLS, so identifying neuropathy or sleep apnea does not automatically rule it out ¹³.

RLS is not the same as periodic limb movement disorder

Periodic limb movements during sleep (PLMS) are a sleep-study finding. Many people with RLS have them, but they are not required for an RLS diagnosis. A person can also have PLMS without feeling any urge to move while awake.

Periodic limb movement disorder (PLMD) is a separate and more restrictive diagnosis. It requires frequent movements on polysomnography plus clinically significant sleep or daytime problems that are not better explained by RLS, untreated obstructive sleep apnea, narcolepsy, REM sleep behavior disorder, or another condition. The 2025 AASM guideline notes that PLMD remains controversial in adults and that current care focuses on RLS symptoms rather than treating a movement count in isolation ².

How RLS is diagnosed

There is no blood test, scan, or sleep-study number that confirms RLS. Diagnosis depends on a careful history showing the four core features and excluding a better explanation ². A clinician may ask:

• what the urge or sensation feels like and where it occurs;
• whether it begins during sitting or lying down;
• what kind of movement helps and how long the relief lasts;
• whether symptoms are worse in the evening or have shifted earlier;
• how often symptoms occur and how they affect sleep, travel, work, or school;
• which prescription, over-the-counter, and recreational substances are used;
• whether symptoms changed with pregnancy, blood loss, blood donation, kidney disease, or a medication change; and
• whether there is a family history of RLS.

A physical and neurological examination may be normal in RLS. Findings such as persistent sensory loss, weakness, swelling, a joint abnormality, or a palpable muscle spasm may support another or additional diagnosis ³.

Polysomnography is not routinely needed to diagnose RLS. A sleep study may be useful when the history suggests sleep apnea, unusual movements, or another sleep disorder. It can record PLMS, but finding leg movements does not prove that they caused a person's symptoms ².

Why iron testing for RLS is different

Iron biology is important in RLS, but having RLS does not automatically mean that a person has anemia or needs an iron supplement. The 2025 AASM guideline advises clinicians to obtain a morning iron panel for clinically significant RLS, including:

• serum ferritin;
• serum iron;
• total iron-binding capacity; and
• transferrin saturation, calculated from iron and total iron-binding capacity.

The guideline advises avoiding iron-containing supplements and foods for at least 24 hours before the draw so the clinician can interpret the results consistently ². Follow the ordering clinician's preparation instructions if they differ.

The RLS treatment thresholds are intentionally different from general-population laboratory reference ranges. The AASM good-practice statement cites consensus thresholds, not empirically validated diagnostic cutoffs: in adults, clinicians may consider oral or intravenous iron when ferritin is at or below 75 ng/mL or transferrin saturation is below 20%; when ferritin is between 75 and 100 ng/mL, the statement routes iron treatment to intravenous rather than oral therapy. The guideline uses a separate ferritin threshold for children ².

These numbers guide a clinician's treatment decision. They do not diagnose RLS, establish the cause of low iron, or make self-started iron safe. Ferritin can rise with inflammation and look reassuring even when available iron is low, which is one reason transferrin saturation matters ³. A normal hemoglobin also does not replace a full iron assessment.

Too much iron can be harmful, and oral and intravenous products have different limitations and adverse effects. A clinician should assess possible blood loss, dietary or absorption problems, pregnancy, kidney disease, inflammation, and iron overload risk before selecting a formulation or monitoring plan ²⁴.

Factors that can cause or worsen symptoms

The biology of RLS is not fully explained by one dopamine or nutrient problem. Genetic susceptibility and altered brain iron regulation appear important. RLS is also more common in conditions associated with systemic iron deficiency, including pregnancy and end-stage kidney disease ².

The first treatment step is to identify modifiable aggravators. The AASM specifically lists alcohol, caffeine, antihistaminergic medicines, serotonergic medicines, antidopaminergic medicines, and untreated obstructive sleep apnea ².

Relevant medicines can include sedating antihistamines in some allergy and nighttime products, some antidepressants, antipsychotics, and dopamine-blocking anti-nausea medicines. This does not mean that everyone with RLS should stop them. The condition being treated and the risks of withdrawal may be more important. Bring a complete list to the prescriber or pharmacist and ask whether timing, dose, or an alternative should be considered.

Obstructive sleep apnea can fragment sleep and complicate the interpretation of limb movements. Snoring, witnessed breathing pauses, gasping, morning headaches, or marked daytime sleepiness should prompt an apnea evaluation rather than an assumption that RLS explains all sleep disruption ²⁵.

Low-risk measures for temporary relief

Mild or intermittent symptoms do not always require medication. The response to self-care varies, and these measures do not correct iron deficiency or replace treatment for clinically significant RLS ⁴.

Reasonable options include:

• brief walking or gentle leg movement when the urge begins;
• comfortable stretching without forcing a painful range;
• heat or cold, light massage, or a change of position if it feels helpful;
• a mentally engaging activity during travel or another unavoidable period of sitting;
• regular physical activity at an intensity that does not worsen symptoms; and
• a stable sleep opportunity, since insufficient sleep can make symptoms harder to tolerate.

Reduce caffeine or alcohol only if the pattern suggests that it aggravates symptoms. A simple log of symptom timing, rest, movement, sleep, medicines, caffeine, and alcohol can make that pattern clearer. The home-remedies guide for RLS gives a focused sequence for short-term relief and its safety limits.

Evidence for acupuncture, herbal products, magnesium, and other supplements is not strong enough to replace diagnosis and guideline-based care. A deficiency should be demonstrated and treated on its own terms rather than inferred from restless legs ²⁴.

Current medical treatment

Treatment is based on symptom frequency and impact, iron status, coexisting conditions, prior therapies, pregnancy status, and the risks of each option. The 2025 AASM guideline represents an important shift away from routine dopamine-first treatment ².

Alpha-2-delta ligands

The AASM strongly recommends gabapentin enacarbil, gabapentin, and pregabalin for adults with RLS. These medicines can reduce RLS severity, but they can also cause sleepiness, dizziness, and unsteadiness ².

The FDA warns that gabapentin and pregabalin can cause serious breathing problems in people with respiratory risk factors, particularly when combined with opioids or other central nervous system depressants and in people with impaired lung function ⁶. Kidney function, fall risk, other sedatives, breathing disorders, and misuse risk therefore belong in the prescribing decision. Do not drive or perform hazardous work if a new medicine makes you sleepy or unsteady.

Iron treatment

Iron treatment is selected from the full iron panel, not from symptoms alone. The AASM strongly recommends intravenous ferric carboxymaltose for adults with appropriate iron status and conditionally supports certain other intravenous formulations and oral ferrous sulfate in defined settings ².

Route and formulation are not interchangeable. Oral absorption becomes limited as ferritin rises, while intravenous products require supervised administration and product-specific monitoring. Iron should be prescribed and followed by a clinician rather than started from a general supplement recommendation.

Why dopamine agonists are no longer routine first-line treatment

Pramipexole, ropinirole, rotigotine, and levodopa can improve RLS in the short term. The 2025 AASM guideline suggests against their standard use because longer treatment can cause augmentation, a medication-induced worsening of RLS ².

Signs of augmentation include:

• symptoms beginning progressively earlier in the day;
• symptoms appearing sooner after sitting or lying down;
• increasing intensity despite treatment;
• spread to the arms or other previously unaffected areas; or
• a growing need for an earlier or larger dose.

Dopamine agonists can also cause impulse-control problems, including new or difficult-to-control gambling, spending, sexual, or eating urges ⁷. A patient or family member should report these changes promptly.

Do not raise the dose or abruptly stop a dopamine medicine on your own. Sudden discontinuation can produce severe rebound symptoms, and a clinician may need to introduce another treatment while tapering it gradually ².

Opioids are reserved treatment

The AASM gives extended-release oxycodone and other opioids a conditional recommendation for adults with moderate-to-severe, refractory RLS. This is not a first-line or self-directed option. It requires careful selection and monitoring because opioids carry risks of sedation, constipation, misuse, physical dependence, overdose, and respiratory depression ².

Combining an opioid with alcohol, a benzodiazepine, a gabapentinoid, or another sedating drug can further suppress breathing. The FDA advises regular risk assessment and specific counseling about overdose and respiratory-depression signs ⁸. Untreated sleep apnea and other breathing risks must be addressed as part of the plan.

RLS during pregnancy or breastfeeding

RLS is common during pregnancy, particularly later in pregnancy, and new pregnancy-related symptoms often improve after delivery. The first steps are to confirm the RLS pattern, check iron status in the pregnancy-specific context, review medicines, and use conservative measures ⁹.

Treatment decisions during pregnancy or breastfeeding cannot be copied from the general adult pathway. Evidence for many RLS medicines is limited, fetal and infant exposure differs by drug and timing, and some dopamine medicines can affect lactation. The AASM advises prescribers to consider the pregnancy-specific safety profile of every treatment ². Coordinate persistent or severe symptoms with the obstetric and sleep-medicine teams, and do not add iron beyond the prenatal plan without review.

RLS in children

Children use the same core diagnostic pattern, but diagnosis can be difficult because a child must describe the urge and sensations in their own words. Growing pains, cramps, discomfort, behavioral restlessness, and sleep apnea can mimic or coexist with RLS ¹².

Pediatric treatment evidence is limited. In the 2025 AASM guideline, ferrous sulfate for children with appropriate iron status is the only recommended treatment, and that recommendation is conditional with very low certainty ². The guideline's pediatric iron threshold is not permission to give a child iron without evaluation. A pediatrician, pediatric sleep clinician, or neurologist should confirm the diagnosis and monitor treatment.

When to seek medical care

Arrange a routine evaluation when the four-feature pattern repeatedly delays sleep, prevents quiet activities, affects mood or daytime function, begins during pregnancy, or becomes more frequent. Contact the prescriber sooner if symptoms began after a medicine change or if treated RLS starts earlier, becomes stronger, spreads, or is accompanied by new compulsive behavior.

Sudden one-sided swelling, redness, warmth, or persistent leg pain is not a typical RLS presentation and needs prompt assessment for conditions such as a blood clot. Chest pain, coughing blood, fainting, or sudden shortness of breath can signal a pulmonary embolism and needs emergency care ¹⁰.

New weakness, persistent numbness, loss of balance, or fixed burning pain also points beyond uncomplicated RLS and warrants medical assessment. Seek emergency care for back or leg pain accompanied by new loss of bladder or bowel control or numbness around the groin ¹¹.

The bottom line

RLS is defined by a specific pattern: an urge to move that begins or worsens at rest, improves with movement, and is worse in the evening or at night. Diagnosis also requires ruling out a better explanation.

Current care starts with RLS-specific iron evaluation, medication and substance review, and treatment of relevant sleep disorders such as obstructive sleep apnea. When medicine is needed, current AASM guidance favors alpha-2-delta ligands and appropriate iron therapy over routine long-term dopamine-agonist treatment. Pregnancy, childhood, refractory symptoms, and possible augmentation need individualized specialist care.